702 TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies

• Wenqing Jiang,
• Zhengyi Wang,
• Jaeho Jung,
• Zhen Sheng,
• Taylor Guo

Affiliations

Wenqing Jiang

1 Department of Respiratory Diseases, Qingdao Haici Hospital, Qingdao, China

Zhengyi Wang

8I-Mab Biopharma, Gaithersburg, MD, USA

Jaeho Jung

3Department of Ophthalmology, Pusan National University Yangsan Hospital, Yangsan, South Korea

Zhen Sheng

1I-MAB Biopharma, Shanghai, China

Taylor Guo

1I-MAB Biopharma, Shanghai, China